Pharmaceutical - Respiratory and Pulmonary, Rare diseases


Popular Filters

Zambon to acquire UK respiratory specialist Profile Pharma


Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

US FDA calls for new trial with Pharmaxis' CF drug Bronchitol


Australian pharma company Pharmaxis (ASX: PXS) says it has received a complete response letter from the…

BronchitolNorth AmericaPharmaceuticalPharmaxisRare diseasesRegulationRespiratory and Pulmonary

Cornerstone Thera gets US rights to Chiesi's Bethkis


USA-based specialty pharma firm Cornerstone Therapeutics Inc. (Nasdaq: CRTX) says it has entered into…

BethkisChiesi FarmaceuticiCornerstone TherapeuticsGenericsLicensingNorth AmericaPharmaceuticalRare diseasesRespiratory and Pulmonary

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis


Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

UK's NICE reverses earlier negative decision on Pharmaxis' CF treatment Bronchitol


Australia's Pharmaxis (ASX: PXS) says that the UK drugs watchdog the National Institute for Health and…

BronchitolEuropePharmaceuticalPharmaxisRare diseasesRegulationRespiratory and Pulmonary

Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren


Spain's largest drugmaker, Almirall (ALM: MC), says that the Danish Health and Medicines Authority has…

AlmirallEklira GenuairEuropeMarkets & MarketingPharmaceuticalPlenadrenRare diseasesRespiratory and PulmonaryViroPharma

Vertex tumbles despite good final data on combo cystic fibrosis therapy


USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF


In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

Vertex slumps as firm revises Kalydeco data


The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

EMA recommends approval of Vertex' CF drug Kalydeco


European Medicines Agency last Friday recommended approval of Kalydeco (ivacaftor), an orphan-designated…

EuropeKalydecoPharmaceuticalRare diseasesRegulationRespiratory and PulmonaryVertex



Back to top